Renaissance Technologies (RenTech)'s CBIO Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 24,262 shares of Crescent Biopharma, Inc. (CBIO) worth $445,693, representing 0.00% of the portfolio. First purchased in 2017-Q1, this long-term strategic position has been held for 31 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in CBIO, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 26,900 shares. Largest reduction occurred in Q1 2026, reducing 22,438 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Crescent Biopharma (CBIO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Crescent Biopharma (CBIO) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -22,438 | Reduce 48.05% | 24,262 | $18.37 |
| Q4 2025 | +19,800 | Add 73.61% | 46,700 | $11.86 |
| Q3 2025 | +26,900 | New Buy | 26,900 | $11.89 |
| Q4 2023 | -5,907 | Sold Out | 0 | $0.00 |
| Q3 2023 | -1,837 | Reduce 23.72% | 5,907 | $48.25 |
| Q2 2023 | -1,015 | Reduce 11.59% | 7,744 | $0.04 |
| Q1 2023 | -3,111 | Reduce 26.21% | 8,759 | $0.02 |
| Q4 2022 | +857 | Add 7.78% | 11,870 | $0.05 |
| Q3 2022 | +3,043 | Add 38.18% | 11,013 | $50.39 |
| Q2 2022 | -3,729 | Reduce 31.87% | 7,970 | $178.04 |
| Q1 2022 | -6,020 | Reduce 33.97% | 11,699 | $65.99 |
| Q4 2021 | +17,321 | Add 4352.01% | 17,719 | $91.43 |
| Q3 2021 | -4,084 | Reduce 91.12% | 398 | $412.06 |
| Q2 2021 | +4,482 | New Buy | 4,482 | $433.07 |
| Q1 2021 | -1,455 | Sold Out | 0 | $0.00 |
| Q4 2020 | -1,055 | Reduce 42.03% | 1,455 | $630.93 |
| Q3 2020 | +1,682 | Add 203.14% | 2,510 | $429.88 |
| Q2 2020 | +395 | Add 91.22% | 828 | $586.96 |
| Q1 2020 | -58 | Reduce 11.81% | 433 | $436.49 |
| Q4 2019 | +491 | New Buy | 491 | $680.24 |
| Q3 2019 | -160 | Sold Out | 0 | $0.00 |
| Q2 2019 | -1,607 | Reduce 90.95% | 160 | $737.50 |
| Q1 2019 | -223 | Reduce 11.21% | 1,767 | $810.98 |
| Q4 2018 | -2,420 | Reduce 54.88% | 1,990 | $788.94 |
| Q3 2018 | -1,456 | Reduce 24.82% | 4,410 | $1078.00 |
| Q2 2018 | +302 | Add 5.43% | 5,866 | $1166.89 |
| Q1 2018 | +2,010 | Add 56.56% | 5,564 | $2579.80 |
| Q4 2017 | +216 | Add 6.47% | 3,554 | $1363.82 |
| Q3 2017 | -59 | Reduce 1.74% | 3,338 | $505.99 |
| Q2 2017 | +2,739 | Add 416.26% | 3,397 | $464.82 |
| Q1 2017 | +658 | New Buy | 658 | $942.25 |
Renaissance Technologies (RenTech)'s Crescent Biopharma Investment FAQs
Renaissance Technologies (RenTech) first purchased Crescent Biopharma, Inc. (CBIO) in Q1 2017, acquiring 658 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Crescent Biopharma, Inc. (CBIO) for 31 quarters since Q1 2017.
Renaissance Technologies (RenTech)'s largest addition to Crescent Biopharma, Inc. (CBIO) was in Q3 2025, adding 26,900 shares worth $319,841.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 24,262 shares of Crescent Biopharma, Inc. (CBIO), valued at approximately $445,693.
As of the Q1 2026 filing, Crescent Biopharma, Inc. (CBIO) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Crescent Biopharma, Inc. (CBIO) was 46,700 shares, as reported at the end of Q4 2025.